Relmada Therapeutics (NASDAQ:RLMD) Trading Up 7.6% – Here’s What Happened

Posted by Brian Himes on May 19th, 2026

Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report)’s stock price was up 7.6% on Tuesday . The company traded as high as $6.81 and last traded at $6.8250. Approximately 330,362 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 1,419,127 shares. The stock had previously closed at $6.34.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on RLMD shares. Mizuho boosted their price objective on shares of Relmada Therapeutics from $10.00 to $19.00 and gave the company an “outperform” rating in a research report on Friday, March 20th. Leerink Partners raised shares of Relmada Therapeutics from a “market perform” rating to an “outperform” rating and set a $8.00 price target for the company in a research report on Friday, January 23rd. Piper Sandler assumed coverage on shares of Relmada Therapeutics in a research report on Tuesday, March 24th. They set an “overweight” rating and a $12.00 price target for the company. Lucid Cap Mkts raised shares of Relmada Therapeutics to a “strong-buy” rating in a research report on Monday, March 2nd. Finally, Zacks Research upgraded shares of Relmada Therapeutics to a “hold” rating in a research note on Tuesday, January 27th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

Get Our Latest Analysis on Relmada Therapeutics

Relmada Therapeutics Trading Up 10.0%

The stock has a market capitalization of $731.61 million, a P/E ratio of -6.37 and a beta of 0.43. The stock’s 50 day simple moving average is $6.87 and its 200 day simple moving average is $5.01.

Relmada Therapeutics (NASDAQ:RLMD – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.04). On average, sell-side analysts expect that Relmada Therapeutics, Inc. will post -0.76 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. XTX Topco Ltd acquired a new position in shares of Relmada Therapeutics in the second quarter worth about $28,000. LMR Partners LLP purchased a new stake in shares of Relmada Therapeutics in the second quarter worth approximately $33,000. Goldman Sachs Group Inc. purchased a new stake in shares of Relmada Therapeutics in the first quarter worth approximately $33,000. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Relmada Therapeutics in the fourth quarter worth approximately $64,000. Finally, Jane Street Group LLC purchased a new stake in shares of Relmada Therapeutics in the second quarter worth approximately $69,000. 45.24% of the stock is currently owned by institutional investors and hedge funds.

Relmada Therapeutics Company Profile

(Get Free Report)

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.